|
|
|
|
Lp-PLA2
SEARCH Search Help Browse by Test Name • Cardiovascular • Coagulation • Endocrinology • General Chemistry • Genetics • Hematology/Oncology • Immunology • Infectious Diseases • Neuropathy • Pharmacogenomics • Toxicology To accurately print this page, please click File, then Page Set-up and select the Landscape orientation.
8...
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
Index F, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - INDEX - Index-A -~ Index-B -~ Index-C -~ Index-D -~ Index-E -~ Index-F-~ Index-G -~ Index-H -~ Index-I -~ Index-J -~ Index-K -~ Index-L -~ Index-M -~ Index-N -~ Index-O ...
|
|
|
Hyperlipoproteinemia: Cholesterol Disorders: Merck Manual Home Edition
Lipid-Lowering Drugs Type Mechanism of Action Indications Side Effects Bile acid binders Cholestyramine Colesevelam Colestipol Binds bile acids in the intestine, causing the acids to be excreted rather than used to make bile and causing the liver to remove more LDL cholesterol from the bloodstream to make bile High LDL cholesterol Constipation, abdominal pain, nausea, bloating,...
|
|
|
Hyperlipoproteinemia: Cholesterol Disorders: Merck Manual Home Edition
Lipid-Lowering Drugs Type Mechanism of Action Indications Side Effects Bile acid binders Cholestyramine Colesevelam Colestipol Binds bile acids in the intestine, causing the acids to be excreted rather than used to make bile and causing the liver to remove more LDL cholesterol from the bloodstream to make bile High LDL cholesterol Constipation, abdominal pain, nausea, bloating,...
|
|
|
Index: FE: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
|
|
|
Fibric acid derivatives for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library
Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Fibric acid derivatives for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Fibric acid derivatives for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Blood and lymph, Heart and circulation, Heart...
|
|
|
050712 Fournier
Solvay Pharmaceuticals -- -- News -- Solvay finalizes agreement to buy Fournier Pharma - This Site- All Sites -Welcome - - Home -Company- -Strategy- -Acquisitions- -Licensing and strategic alliances- -Mission, Vision, Values- -Organization- -Marketing and sales- -Research and Development- -Manufacturing- -Our corporate offices- -Part of Solvay- -History- -Facts and figures- -In the...
|
|
|
BioPortfolio Limited
163 Statin choice for diabetic dyslipidemia 176 Breakdown of statin prescribing by line of therapy 181 Breakdown of statin prescribing by daily dose 183 Reimbursement restrictions in Japan promoting low dose statins 187 Factors limiting the use of higher statin doses 187 Less potent statins require higher doses 189 Brand versus generic statin prescribing: current and future trends...
|
|
|
Teva Pharmaceutical Industries - News and PR
- - Search Tevapharm: - - Press Releases 2004 - 2005: Teva Announces Approval Of Methylprednisolone Acetate Injectable Suspension Jerusalem, Israel, February 24, 2005 Teva and Lundbeck Announce European Approval for AZILECT® (rasagiline) 1mg for Parkinson's Disease Jerusalem, Israel and Copenhagen, Denmark, February 22, 2005 Teva Announces Settlement Of Lamictal® Litigation...
|
|
|
Teva Pharmaceutical Industries - News and PR
- - Search Tevapharm: - - Press Release Teva Announces Resolution of Patent Litigation for Fenofibrate Capsules Jerusalem, Israel, March 21, 2002 - Teva Pharmaceutical Industries Ltd.
District Court of Illinois has granted Summary Judgement of Non-infringement regarding Teva’s ANDA for Fenofibrate Capsules (Micronized).
Teva Pharmaceutical Industries Ltd.,...
|
|
|
Teva Pharmaceutical Industries - News and PR
- - Search Tevapharm: - - Press Release Teva Announces Approval of Fenofibrate Capsules Jerusalem, Israel, April 10, 2002 - Teva Pharmaceutical Industries Ltd.
Food and Drug Administration has issued final approval for the company’s ANDA for Fenofibrate Capsules (Micronized), 134 mg and 200 mg, and has granted tentative approval for the 67 mg strength.
A recent...
|
|
|
Teva Pharmaceutical Industries - News and PR
- - Search Tevapharm: - - Press Release Teva Announces Approval of Fenofibrate Capsules (micronized), 67mg.
Food and Drug Administration has granted final approval for the company’s ANDA for Fenofibrate Capsules (Micronized), 67 mg.
As the first company to file an ANDA with a Paragraph IV patent certification, Teva has been awarded 180 days marketing...
|
|
|
Teva Pharmaceutical Industries - News and PR
- - Search Tevapharm: - - Press Release Teva Announces Tentative Approval Of Fenofibrate Tablets, 54 Mg, 160 Mg Jerusalem, Israel, March 8, 2004 - Teva Pharmaceutical Industries Ltd.
Food and Drug Administration has granted tentative approval for the Company’s ANDA for Fenofibrate Tablets, 54 mg and 160 mg.
Fenofibrate Tablets are the AB-rated generic...
|
|
|
Teva Pharmaceutical Industries - News and PR
will Have 180 Days of Marketing Exclusivity Jerusalem, Israel, September 4, 2002 Teva Announces Final Approval for Nifedipine ER 90mg Tablets Jerusalem, Israel, August 19, 2002 Teva Comments on Court Affirmation of Relafen® Patent Challenge Jerusalem, Israel, August 16, 2002 Teva Announces Approvable Status of Gabapentin Capsules Jerusalem, Israel, July 22, 2002 Teva to Report...
|
|
|
SkyePharma | Product
- Oral Sanofi-Aventis Xatral® OD/ Uroxatral® Genito-Urinary Marketed Roche Madopar DR® Parkinson's Disease Marketed Ratiopharm Diclofenac Arthritis Marketed Mundipharma Cordicant-Uno® Hypertension Marketed GlaxoSmithKline Paxil CR™ CNS Marketed Therabel Coruno® Angina Marketed GlaxoSmithKline Requip® Parkinson's Disease Phase III Nitec Undisclosed...
|
|
|
SkyePharma
March 4, 2005 SkyePharma PLC - Paxil CR Clarification February 1, 2005 SkyePharma and First Horizon Extend Agreement for Novel Formulation of Fenofibrate December 6, 2004 SkyePharma Announces US Launch of DepoDur™ Stock Quote (20 min delay) SKP.L £- 0.55 0.00 SKYE $- 10.599 +0.099 SkyePharma SkyePharma.
|
|
|
Microsoft PowerPoint - 07 FRESCO 2004 Mark Fishman_ 2005-01-20_Analysts.ppt
1 Novartis Institutes for BioMedical Research Mark C.
Chronic myeloid leukemia (CML) resistant to Glivec ®1 : AMN107 3.
Metabolic syndrome and diabetes: LBM642 2.
Follow-up is short (cytogenetic responses to Glivec ® may take 3-6 months) Hematologic response rate Cytogenetic response rate 63 58 50 20 8 17 0 10 20 30 40 50 60 70 Accelerated phase Myeloid blast phase...
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
|
|
|
Microsoft PowerPoint - 07 FRESCO 2004 Mark Fishman_ 2005-01-20_Analysts.ppt page 6
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
|
|
|
Microsoft PowerPoint - 07 FRESCO 2004 Mark Fishman_ 2005-01-20_Analysts.ppt page 5
author: releano1
duplicates:
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
http://www.novartis.com/downloads_new/investors/fresco_analysts_presentation%20_01_2005/07%20FRESCO%202004%20Mark%20Fishman_%202005-01-20_Analysts.pdf
|
|
|
June | Hot Topics in Healthcare
- - Trouble navigating this site
CoQ(10) plays a vital role in a number of complexes involved in this process.(6) The biochemical background for CoQ(10) was reported in this newsletter recently.(7) Administration of CoQ(10) has thus been proposed to compensate for the effects of mtDNA mutations, which lead to fewer mitochondria and less mtDNA in those that are made
An...
|
|
|
http://www.adis.com/files/newsletters/INP/Icov1436.pdf
20 Quinupristin/ dalfopristin effective in VREF infections 14 ALLERGY Smallpox vaccine trial suspended due to myopericarditis 16 Desloratadine for chronic idiopathic urticaria, SAR 5 Politics, lack of funds jeopardise eradication of polio 4 CANCER RSV infection prophylaxis in infants 3 Gefitinib in NSCLC: EGFR mutations and response 13 MUSCULOSKELETAL Leuprorelin (sustained- release)...
|
|
|
http://www.adis.com/files/newsletters/REA/Rxcov993.pdf
16 Doxorubicin/ vincristine/ cyclophosphamide: triple primary lung 8 Pharmacovigilance & Regulatory News cancers [S] Olanzapine/ risperidone not for use in elderly with dementia 2 Fenofibrate: acute hepatitis and cholestatic jaundice [S] 9 Paroxetine: UK CSM issues reminder regarding starting dose 2 Fentanyl/ morphine/ bupivacaine: interaction with concomitant 12 Risperidone/...
|
|
|
Pcr03index-5.0.qxd page 4
author: mcintosht
|
